The global blood glucose monitoring devices market size was valued at USD 15.82 billion in 2025 and is projected to grow from USD 16.97 billion in 2026 to USD 29.68 billion by 2034, registering a CAGR of 7.24% during the forecast period (2026-2034). North America dominated the blood glucose monitoring devices market with a share of 41.37% in 2025.
Blood glucose monitoring devices are medical diagnostic instruments used to measure glucose levels in the blood. They are classified under HSN Code 9027.89 (instruments for physical or chemical analysis) and SIC Code 3845 (electromedical and electrotherapeutic apparatus).
The blood glucose monitoring devices market demand is driven by the high prevalence of diabetes and the need for regular glucose monitoring. The adoption of continuous glucose monitoring systems and smartphone connected devices supports market growth.
Download a Free Sample To learn more about this report,
Adoption of Over-the-Counter Continuous Glucose Monitoring Devices
The blood glucose monitoring devices market analysis indicates increasing adoption of over-the-counter continuous glucose monitoring systems among individuals who do not use insulin. For example, Abbott's Lingo biosensor is available through more than 3,500 Walmart stores across the U.S., reflecting wider retail accessibility and growing consumer interest in glucose monitoring.
Development of Minimally Invasive Glucose Microsensors
Development of minimally invasive glucose microsensors is gaining attention as manufacturers seek to reduce discomfort associated with conventional glucose monitoring. These devices use compact sensors to measure glucose levels beneath the skin. Manufacturers are focusing on longer sensor wear periods and simplified application.
Supply chain disruptions are expected to have a moderate impact on the blood glucose monitoring devices market share due to shortages of semiconductor chips, glucose sensors, and electronic components. The market is expected to experience a K-shaped recovery as established manufacturers with diversified suppliers can restore production faster. Smaller manufacturers remain vulnerable to component shortages and higher procurement costs. The market is projected to grow at a CAGR of 7.24%. Supply constraints could temporarily reduce growth by 1.5 percentage points to 5.74%. Improved component availability and stable production capacity could support recovery toward 7.24%.
The blood glucose monitoring devices market forecasts continued investment in continuous glucose monitoring technologies, sensor development, and manufacturing expansion.
Key Investment and Funding Activities in Blood Glucose Monitoring Devices Market, 2025–2026
Expanding Insurance Coverage for Continuous Glucose Monitoring and Use of Bedside Glucose Testing in Critical Care Drives Market
Reimbursement policies reduce out-of-pocket expenses and encourage long-term adoption of glucose sensors. For example, U.S. Medicare covers continuous glucose monitors for eligible insulin-treated patients and individuals with a documented history of problematic hypoglycemia. This coverage supports higher device utilization and recurring demand for replacement sensors in diabetes management.
Need for bedside glucose testing in critical care units is strengthening demand for hospital-grade blood glucose monitoring devices. According to the American Diabetes Association's 2026 guidelines, patients receiving intravenous insulin typically require glucose monitoring every 30 minutes to 2 hours. This frequent testing requirement supports recurring demand for point-of-care glucose meters and test strips.
High Recurring Sensor Replacement Costs and Sensor Accuracy Limitations Restrain Market Adoption
The recurring cost of continuous glucose monitoring sensors remains a major restraint for patients without adequate insurance coverage. Unlike conventional glucose meters, continuous monitoring systems require periodic sensor replacement. This increases long-term monitoring expenses and limits affordability in price-sensitive markets.
Continuous glucose monitoring devices measure glucose in interstitial fluid rather than directly in the blood. This can cause differences between sensor readings and actual blood glucose levels during rapid glucose changes. Sensor adhesion problems and skin irritation may also affect prolonged use.
Development of Longer-Lasting Glucose Sensors and Integration of Multianalyte Biosensors Creates New Market Opportunities
Advancements in extended-wear glucose sensors are creating opportunities to improve convenience and reduce sensor replacement frequency. Longer sensor lifespans can lower monitoring interruptions and improve patient adherence. For example, Dexcom's G7 15 Day sensor offers a wear period of 15 days with an additional 12-hour grace period. This technology encourages manufacturers to develop durable sensors with improved stability and reduced replacement requirements.
The development of multianalyte biosensors presents opportunities for manufacturers to expand beyond conventional glucose monitoring. These devices are being designed to measure glucose alongside other biomarkers, particularly ketones, through a single wearable sensor. Combined monitoring could help insulin-dependent patients identify metabolic changes without using separate testing devices.
Self-monitoring blood glucose systems dominated the service segment with a share of 52.50% in 2025, owing to their lower device costs and established use in finger-prick testing. Affordable test strips and simple operating procedures support continued adoption among patients requiring periodic glucose checks.
The continuous glucose monitoring systems segment is likely to witness a CAGR of 10.50% during the forecast period. This growth is attributed to growing demand for automated glucose tracking. The increasing use of real-time glucose alerts among insulin-treated patients supports segment growth.
Request Customizationto receive a tailored report.
Type 1 diabetes is expected to achieve a growth rate of 8.50% during the forecast period, due to the need for intensive glucose monitoring during insulin therapy. Frequent glucose fluctuations and hypoglycemia risks support sustained demand for accurate monitoring systems.
Type 2 diabetes segment is projected to undergo growth at a CAGR of 6.60% during the forecast period due to increasing demand for glucose monitoring during treatment adjustments. The growing number of insulin-treated Type 2 diabetes patients supports segment growth.
Home care dominated the end user segment in 2025, accounting for a share of 65.80%. This dominance is attributed to growing adoption of portable glucose meters for routine diabetes management. The convenience of self-testing and reduced need for frequent hospital visits support segment growth.
Diagnostic centers segment is estimated to register a growth rate of 6.50% during the forecast period, owing to expanding use of point-of-care glucose testing in outpatient diagnostic facilities. The need for rapid glucose assessment and timely clinical decisions supports segment expansion.
Speak to an Analystto discuss market opportunities.
The North America blood glucose monitoring devices market accounted for the largest regional share of 41.37% in 2025.
Centers for Medicare & Medicaid Services covers these devices for insulin-treated beneficiaries and patients with documented problematic hypoglycemia. Medicare also requires periodic clinical assessment to maintain coverage. This reimbursement framework improves access to prescription glucose sensors and supports recurring demand for monitoring supplies among eligible patients.
Diabetes Canada reports that Ontario provides coverage for up to 3,000 test strips annually for eligible patients using insulin. Provincial coverage arrangements encourage continued self-monitoring among diabetes patients. Differences in reimbursement eligibility also create opportunities for manufacturers offering affordable glucose monitoring solutions across Canadian provinces.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific blood glucose monitoring devices market is expected to grow at a CAGR of 9.68% during the forecast period, showcasing the fastest-growing regional market.
Healthy China Diabetes Prevention and Control Action Plan for 2024–2030 shapes the Chinese market. The National Health Commission aims to achieve standardized primary-level management coverage of at least 70% for patients with Type 2 diabetes by 2030. The plan also encourages wearable glucose monitoring technologies.
According to the Ministry of Health and Family Welfare, approximately 181,873 centers were operational as of November 2025, with 36.70 crore diabetes screenings reported. This extensive primary healthcare network strengthens access to blood glucose testing and supports demand for affordable point-of-care glucose meters in underserved communities.
Ministry of Health, Labour and Welfare provides reimbursement provisions for eligible continuous glucose monitoring systems, including devices used with insulin pumps. These arrangements encourage glucose monitoring among patients receiving intensive insulin therapy. The country's specialized diabetes care infrastructure supports continued demand for glucose sensors and compatible monitoring equipment.
Europe's blood glucose monitoring devices market is estimated to grow at a CAGR of 6.50% during the forecast period.
UK market is shaped by NHS England's implementation of hybrid closed-loop technology for eligible patients with Type 1 diabetes. These systems integrate continuous glucose monitors with insulin pumps to automate insulin delivery adjustments. The NHS reimbursement framework improves patient access to advanced glucose monitoring systems. The growing integration of automated insulin delivery technology into routine diabetes care supports demand for compatible glucose sensors and monitoring devices.
Germany supports statutory health insurance coverage for real-time continuous glucose monitoring among eligible insulin-dependent patients. The Federal Joint Committee recognizes these systems for patients requiring intensive insulin treatment under specified clinical conditions. This reimbursement structure encourages the use of sensor-based glucose monitoring in diabetes care. Established outpatient diabetes practices support continued device utilization and sensor replacement demand.
The Latin America blood glucose monitoring devices market is expected to grow at a CAGR of 7.40% during the forecast period. In Brazil, the Unified Health System (SUS) provides glucose test strips and lancets to eligible insulin-dependent patients. The Ministry of Health recommends three to four glucose tests daily for insulin users, supporting recurring demand for testing supplies.
Mexico's Social Security Institute (IMSS) is strengthening diabetes care through continuous glucose monitoring patches and point-of-care testing equipment. These technologies support glucose assessment and monitoring among patients receiving public healthcare services.
The Middle East & Africa blood glucose monitoring devices market is projected to grow at a CAGR of 7.10% during the forecast period. In the UAE, Abu Dhabi's Department of Health recommends continuous glucose monitoring for adults and children with Type 1 diabetes. The guidelines also support its use among selected insulin-treated Type 2 diabetes patients, strengthening demand for wearable glucose sensors.
South Africa's public healthcare guidelines recommend home glucose monitoring three to four times daily for adults with Type 1 diabetes receiving basal-bolus insulin therapy. This requirement supports recurring demand for glucose meters and test strips.
The blood glucose monitoring devices market competitive landscape is consolidated, with established manufacturers dominating continuous glucose monitoring and major companies competing in conventional glucose testing. Key players such as Abbott Laboratories, Dexcom, Roche, Medtronic, Ascensia Diabetes Care, and LifeScan are estimated to account for over 80% of the global continuous glucose monitoring market share.
Established companies compete through sensor accuracy, reimbursement access, and distribution networks. Emerging manufacturers in the blood glucose monitoring devices market ecosystem focus on affordable testing systems, extended sensor wear, and minimally invasive monitoring technologies/
August 2026: Abbott Laboratories partnered with Google Health to integrate glucose data from its Lingo continuous glucose monitor with AI-powered personalized health insights.
July 2026: Dexcom received Health Canada authorization for its G7 15 Day continuous glucose monitoring system, offering up to 15.5 days of sensor wear for adults with diabetes.
June 2026: Dexcom announced the acquisition of Nutrisense to expand personalized nutrition coaching and continuous glucose monitoring services for diabetes management.
January 2026: Medtronic received U.S. FDA clearance for its MiniMed Go Smart MDI system, integrating Abbott's Instinct glucose sensor with insulin dosing data through a mobile application
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Electrophysiology Market Size, Forecast, Opportunities, 2034
Autoclaves Market Size, Forecast, Demand, Opportunities, 2034
X-Ray Detector Market Size, Share, Growth, Analysis, Report, 2034
Blood Pressure Transducers Market Size, Forecast, Opportunities, 2034
3D Printed Prosthetics Market Size, Forecast, Demand, Opportunities, 2034
We are featured on:
sales@straitsresearch.com